Ben Franklin Technology Partners of Southeastern Pennsylvania
Capital Briefings
Registration
Home About BFTP SEP Portfolio Newsroom Events Contact Us
Capital Knowledge Networks Partners Site Index Discussion Forums Careers Administration Board of Directors Advisory Committees 2008 Performance Profile 5-Year Plan Portfolio Sponsored Programs Ben Franklin Statewide Success Bldg 100 Innovation Ctr Tenants

CAPITAL

LIFE SCIENCES
Next proposal due January 13, 2010. It is strongly recommended to submit an Executive Summary at least 2 weeks before the proposal is due.



Life Sciences Investment Levels:

Funding Info and Application Stage of Company Funding Amount
Innovation Company Investments
doc		 Proof of concept or prototype development/refinements Up to $100,000
Application Fee: $500
Commitment Fee*:1% of the full funds amount
Emerging Company Investments
doc		 Early Stage Seed Capital for further product or process development and commercialization efforts $101,000-$500,000
Application Fee: $500
Commitment Fee*:1% of the full funds amount
Fund Purpose Funding Amount
Technology Commercialization Fund
doc		 Spin out situations with academic and research institutions where a Company is formed surrounding a technology discovered and licensed by universities or research institutions Up to $350,000 Application Fee: $500
Commitment Fee*:1% of the full funds amount
*Commitment fee - Subject to BFTP/SEP loan approval, due upon signing of closing documents

Life Sciences Funding Documents
  • Program Information Instructions: doc
  • Executive Summary: doc
  • Application: doc
  • Budget: xls
  • Milestones: xls
Overview
BFTP/SEP has a strong track record of providing early-stage financing and entrepreneurial guidance to promising life sciences ventures across a span of technologies including: biopharmaceuticals, medical devices, diagnostics, biomaterials, and healthcare IT.
We have funded many of southeastern Pennsylvania's leading life science companies, including Centocor (NYSE: JNJ), Cephalon (Nasdaq: CEPH), Adolor (Nasdaq: ADLR), ViroPharma (Nasdaq: VPHM), Orthovita (Nasdaq: VITA), Genaera Corporation (Nasdaq: GENR), Immunicon (Nasdaq: IMMC), Ecton (acquired by Siemens), Annovis (acquired by Transgenomic), BioSyn (acquired by Cellegy Pharmaceuticals), and Morphotek.
As BFTP/SEP seeks to invest in only the most promising early stage life sciences companies, funding is extremely competitive. Most of the companies successful in raising BFTP/SEP funding possess the following characteristics:
  • Venture experienced business management
  • Strong IP and patent protection
  • Novel and unique science
  • Sound business and scientific approach
  • Leveraged sources of capital (SBIR, Angel, Early Stage Venture Capital, other state funding sources)
  • Ability to achieve a significant milestone with BFTP/SEP dollars
  • Long term sustainability and job creation
Investment Levels
BFTP/SEP invests $100,000 - $500,000 as part of larger funding rounds of $200,000 - $3,000,000 involving other sources such as SBIR, Angel, Early Stage Venture Capital, and other state funding sources.
It is expected that companies funded by the Biotechnology and Life Sciences Investment vertical will achieve a significant commercial and/or technical milestone that attracts additional outside investors (Angel, Venture Capital, Government Funds), strategic partners, and/or will generate revenue.
Terms
BFTP/SEP's standard investment terms for Life Science companies include:
  • Convertible Debt
  • Warrant
  • Negative Pledge (on technology)
  • Board Observation Rights
  • BFTP/SEP reporting compliance
Term Details: pdf
For more information contact:

Last Modified:
12/02/09

©2009 Ben Franklin Technology Partners of Southeastern Pennsylvania
Building 100 Innovation Center | 4801 S Broad St, Suite 200
The Navy Yard | Philadelphia, PA 19112
Tel. 215.972.6700 | Fax 215.972.5588 | info@sep.benfranklin.org

Directions to the Navy Yard